Andreas Wicki
Zürich, Switzerland
Andreas Wicki is a Series C investor at HBM Healthcare Investments in Zürich focused on Medical and Health Care. Andreas Wicki is the Founder & CEO of HBM Partners.He attend to the University of Bern in 1980.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Andreas Wicki invests in
Stages Andreas Wicki invests in
Countries Andreas Wicki invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (33%)
- Health Care 3 (33%)
- mHealth 1 (11%)
- Delivery 1 (11%)
- E-Commerce 1 (11%)
Stage
- Series C 2 (22%)
- Series B 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
- Debt Financing 1 (11%)
Country
- United States 2 (22%)
- India 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | $17.8M / Debt Financing / Jul 03, 2020 | ||
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | $70M / Series D / Jun 28, 2019 | ||
| YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on thedevelopment of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval. | $30M / Private Equity / Nov 29, 2017 | ||
| YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on thedevelopment of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval. | $50M / Private Equity / Oct 24, 2017 | ||
| BaseHealth is a predictive health platform that is evidence-based and data-driven without reliance on retrospective claims and ICD data. The company’s proprietary platform leverages machine learning to sift through millions of medical journals and patient records curated by scientists and physicians to offer healthcare providers the ability toidentify patients with underlying risks for 43 chronic diseases and prevent costly treatments before they’re needed. It was founded in 2008 and headquartered in Sunnyvale, California. | $8.5M / Series C / Oct 18, 2017 | ||
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | $15M / Series C / Jul 26, 2017 | ||
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | $10M / Jun 30, 2017 | ||
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | May 31, 2016 | ||
| 1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professionalfor a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.The company empowers Indian consumers and caregivers to select the appropriate healthcare service at the best possible price. 1mg was launched in 2015 and its operations are headquartered in Gurgaon, Haryana, India. | Series B |
Co-Investors
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
HBM Healthcare Investments Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Benedikt Suter
Secretary to the Board
|
|||
Mario G. Giuliani
Member of the Board of Directors
|
|||
|
Andreas Wicki
CEO
|
|||
Erwin Troxler
CFO
|
|||
Hans Peter Hasler
Chairman, Board of Directors
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Andreas Wicki invest in?
Andreas Wicki invests primarily in Medical, Health Care and mHealth startups, most often at Series C and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andreas Wicki?
Public channels for Andreas Wicki include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andreas Wicki last invest?
The most recent investment recorded for Andreas Wicki closed in Jul 2020. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
